Thomas Hagemeijer’s Post

So many HealthTech startups begin their journey with a desire solve problems which cause patients' pain. This holds true for JVPLabs (JRAS Medical Inc.). Dr. Andrew J. Smith, MD, noticed many of his heart failure patients would find themselves in fearsome instances, feeling short of breath in the emergency room. To mitigate this experience, JVPLabs has developed a non-evasive method for heart monitoring in a patient's home. The solution uses a complex camera system which detects pressures inside the heart, providing data so that medical staff can adjust medication without patients even leaving their home. Some much needed innovation for those struggling with heart failure ❤️🩹 Learn more 🔗: www.jvplabs.com #HeartFailure #PatientMonitoring #HealthTech #Newfoundland

Here’s Reinhard Krickl, CEO of Phagenesis Ltd, quoting his co-founder Conor Mulrooney:  “What's important is not what your device can do, but what it can do for the end user. So it's not about the features and all the cool technology you’re developing. It's really what's going to net the biggest impact in the hands of the user. What is it going to solve for them?” Reinhard is an engineer turned #medtech entrepreneur who thinks transforming patient care through technology is “the most exciting thing you can do.” Under his leadership, Phagenesis is commercializing a neurostimulation system designed to treat dysphagia—difficulty in swallowing—which affects millions of patients globally, especially after stroke or extensive ventilator use. Here's a sneak peek at Reinhard’s conversation with Scott Nelson: ☘️ Simplify for impact: In medtech, focus less on features that don’t contribute to usability or functionality and more on intuitive design that solves real user needs. Understand your market by engaging stakeholders with an open mind. 🧩 Understand the ecosystem: Know how your tech fits into the clinical workflow. Additionally, structural dynamics, such as regulatory requirements, reimbursement policies, and standard of care procedures, can either hinder or facilitate the adoption of your device. 👁️🗨️ Consistent investor communication is crucial for securing funding. When it comes to pitching, you have to be able to tell an engaging story. Use every opportunity, regardless of the outcome, as a learning experience. Learn more from Reinhard’s experience in medtech [link in comments]. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We recently launched Medsider Mentors Volume VI, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.

I am very thrilled to announce that we have recently participated in follow-on rounds of existing portfolio companies as well as backed two new exciting digital health companies: Doccla is the leading remote patient monitoring provider in Europe led by Dag Larsson and Martin Ratz. In their recent round led by Lakestar, and supported by Elaia and Optum Ventures we are excited to keep supporting their journey alongside General Catalyst, Giant Ventures, Speedinvest deepc, an orchestration platform for AI, starting with Radiology as the first vertical and led by Dr. Franz MJ Pfister, MD, MBA, where we followed-on alongside Sofinnova Partners with participation from new strategic investors KHP Ventures and SwissHealth Ventures who are supporting the market expansion Guardoc Health led by Hadassah Backman develops a compliance integrity platform to support understaffed and heavily overworked nursing staff with daily documentation, ensure compliance with regulations and improve the audit and billing process in care homes. We seeded the company together with our friends Pitango and the US investor Springbank among others Pi Health led by Geoffrey Kim and Bobby Reddy, MD has built an unique end-to-end software stack for clinical trials. Pi Health was recently spun out of BeiGene, and we invested in their series A together with AlleyCorp and Obvious Ventures    These investments take our Bertelsmann Investments Next growth program to yet another level.   We’re proud to backing the exceptional founders and their teams. We are fully convinced that these companies do make an important contribution to improving healthcare.   cc: Thorsten Wirkes Tim Schneider Agnes Eva Uhr, LL.M. Maximilian Boner #BertelsmannNext #VentureCapital #DigitalHealth #Growth #HealthcareInvestments https://lnkd.in/eDm4JXAh

📢 We are excited to announce our investment in Cala Health, a pioneering bioelectronic medicine company revolutionizing tremor treatment.   The Cala kIQ System with TAPS™ Therapy represents a significant breakthrough for patients with essential tremor and Parkinson's disease by offering a clinically proven, FDA-approved wearable device alternative to traditional treatment methods. With over 7 million people in the United States impacted by essential tremor, Cala Health's innovative approach addresses an unmet medical need.    As co-lead investors in their US$50 million growth round, we are excited to partner with their exceptional team, led by CEO Deanna Harshbarger, as they continue to expand patient access and clinical evidence for their revolutionary technology.   Read more: https://lnkd.in/g8zKRVz3 James Lee Yue (Shelby) Zhang #MedicalInnovation #HealthTech #BioelectronicMedicine #VentureCapital #Startups

“You've got to balance the idea that the doctors that first work with you are going to understand that they have technology that isn't complete, that this isn't the final generation. But you need to have developed it in such a way that there is a real path to that final version.” Dan Rose is back on Medsider to share his proven #medtech insights after LimFlow SA’s recent exit to Inari Medical. With 25 years of experience in both startups and industry giants like Medtronic, Dan talks about M&A transactions, engaging with investors while maintaining business autonomy, and the importance of developing your #medicaldevice with the average user in mind. LimFlow’s technology tackles Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) – conditions where blocked arteries threaten limb viability and may potentially lead to amputation. Instead of trying to open blockages, LimFlow ingeniously reroutes blood flow through adjacent veins, restoring circulation and offering hope to patients who suffer from this disease. Here’s a sneak peek into his interview with Scott Nelson: ⚖️ Vet your potential investors carefully and consider how their involvement will impact your business operations, especially if there are multiple parties involved. Limit their influence on decision-making to maintain flexibility and control over your company's direction. 🥼 In the early development phases, design for the average user to maximize adoption rates. Always iterate towards simplicity and be prepared to pivot accordingly. And don't hold onto complex elements or features simply because they were part of the original plan. 💵 Understanding the reimbursement landscape and how your technology fits into that is crucial to progress your conversations with VCs. Research potential investors to ensure that they have the capacity to invest and that their interests match your company's focus. Click on the link in the comments section to follow Dan’s journey building and exiting LimFlow. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We just launched Medsider Mentors Volume V, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.

Our CEO & Founder, Kelvin Summoogum, has been busy in Phoenix, Arizona, for the MedTech Accelerator! Uncover MiiCare’s origins, and why we’re so determined to change the way we approach care for older adults. 🌵 At MiiCare, our journey is deeply personal and rooted in compassion. Kelvin was inspired to take action after witnessing his father's struggles. Determined that "nobody should go through that same pain as my father," and thus, MiiCare was born… to change the lives of older adults around the world. 🌍❤️ From Monica, our intelligent companion, to our comprehensive insights dashboard and reporting, we are on a mission to positively impact 1 billion lives by 2030. 🌟 In #collaboration with Mayo Clinic and Arizona State University, this incredible opportunity is paving the way for groundbreaking advancements in the US healthcare system. 🌐 As part of this prestigious cohort, we are engaging with industry leaders, gaining access to cutting-edge medtech innovations, and leveraging the combined expertise of ASU and Mayo Clinic. Our dedication to creating impactful solutions aligns perfectly with the Accelerator's mission to advance healthcare through technology, including #AI, and more. We are thrilled to contribute to this vibrant ecosystem and significantly impact population health outcomes at scale. 🌟 Watch our official video for the Accelerator here: https://lnkd.in/eHezbDX5 #MedTech #HealthcareInnovation #PopulationHealth #TechForGood #HealthcareTransformation

As part of our ongoing ELEVATE US HealthTech programme in partnership with Cedars-Sinai Technology Ventures, startups learnt about “US Healthcare Payor Landscape and Reimbursement” from Lori Weaver, Director of Managed Care & Payor Relations at Cedars-Sinai. Lori gave an overview of the intricate healthcare reimbursement system and shed insights on payor mix and its importance in the context of US healthcare. Lori’s session ignited exciting discussions, and startups got a sight of what it took to have their innovative solution be adopted into the US healthcare system. This week on spotlight is Carecam, a #deeptech venture that redefines therapeutics using human motion. Through their 3D Gait solution, Carecam is revolutionizing movement disorder management and preventive healthcare, all without the need for expensive wearables/sensors. With the ELEVATE US HealthTech Programme, Carecam is looking to set up intervention programs in the US for patients suffering from movement disorders. CEO Elson Yong Ching Kiat, values these opportunities to engage with KOLs in the Cedars-Sinai healthcare ecosystem, and shares that these “interactions have provided invaluable feedback and perspectives, enabling us to refine our product and tailor it to better meet the needs of both healthcare providers and patients”. With this opportunity to work closely with Cedars-Sinai, Carecam are stepping closer to unlock their US market entry plans!  

Mayo Clinic is one of the most active health systems in partnering with #digitalhealth, boasting close to 120 partnerships. Most recently, Mayo Clinic announced a partnership with Exer AI, a clinical AI focused on MSK and motion disorders. On average, six new partnerships are announced per quarter, primarily from the U.S., but recently also from Israel, Singapore, Finland, and Germany. Based on the data, it is clear that Mayo Clinic helps its partners gain traction and, more importantly, credibility. Of the 14 Seed-stage ventures Mayo Clinic partnered with, five progressed to Series A and B stages within 24 months. Of the 25 ventures Mayo Clinic partnered with during their Series A stage, four have progressed to Series B-D funding stages, and four exited through M&A. While most solution partners are focused on #diagnostics (34%), #healthmanagement (11%) and #patientsolutions (9%) have also gained traction recently. With #AlphaEdge in HealthTech Alpha, you can analyze corporate and investor portfolios in real-time to make informed decisions. Galen Growth | Insights You Can Trust

This week, we bring you insights from two Medsider trailblazers who’ve shaped the landscape of healthtech and biotech. First, we look at John Mastrototaro's journey -  from his groundbreaking work in diabetes care to launching the Movano Ring, a smart wearable transforming how consumers manage their health with data-driven insights. Next, we revisit Caroline J Loew, PhD, CEO of Mural Oncology and former CEO of Glympse Bio (Sunbird Bio), who takes us behind the scenes of her biotech journey - from developing groundbreaking biomarker panels to tackling regulatory hurdles. Here’s a sneak peek at two of our exclusive interviews: 𝐇𝐨𝐰 𝐭𝐨 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐡𝐞 𝐂𝐨𝐧𝐬𝐮𝐦𝐞𝐫 𝐇𝐞𝐚𝐥𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐈𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐰𝐢𝐭𝐡 Movano Health 𝐂𝐄𝐎 𝐉𝐨𝐡𝐧 𝐌𝐚𝐬𝐭𝐫𝐨𝐭𝐨𝐭𝐚𝐫𝐨 📊 How John demonstrated to payers and patients how the Movano Ring could reduce traditional healthcare costs. 💍 How Movano ensured consistent use of its wearable by prioritizing design alongside functionality. 𝐂𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 𝐖𝐢𝐧 𝐎𝐯𝐞𝐫 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬: 𝐈𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐰𝐢𝐭𝐡 𝐆𝐥𝐲𝐦𝐩𝐬𝐞 𝐁𝐢𝐨 𝐂𝐄𝐎 𝐂𝐚𝐫𝐨𝐥𝐢𝐧𝐞 𝐋𝐨𝐞𝐰 💸 The 4 strategies Caroline used to raise funds during the pandemic year when markets were at their lowest. 🤓 How her flexible and proactive approach with regulators was key to navigating the regulatory process successfully. PS - We've revamped our exciting new features exclusively for Medsider premium members: ⭐ Playbooks: Go from 0 to 100 with hand-picked collections of the best Medsider interviews with the brightest founders and CEOs. ⭐ Investor database: 3 new fundraising support packages to fit your needs. Find your next #medicaldevice or #healthtechnology investor with Medsider.